<DOC>
	<DOCNO>NCT00778050</DOCNO>
	<brief_summary>This study compare relative bioavailability ( rate extent absorption ) amoxicillin tablet oral suspension 600 mg Ranbaxy Laboratories Limited Amoxil ® oral suspension 400 mg/ 5 mL SmithKline Beecham Pharmaceuticals follow single oral dose ( 600 mg ) healthy , adult , subject fast condition use randomize two-way crossover design .</brief_summary>
	<brief_title>Bioequivalence Study Amoxicillin Dispersible 600 mg Tablets Under Fasting Conditions</brief_title>
	<detailed_description>A single oral dose test reference product administer volunteer two separate occasion fast condition least 7 day washout dos . Twenty-six healthy volunteer randomly assign test reference product . Food fluid intake control confinement period . Twenty six ( 26 ) healthy subject ( 16 male 10 female ) enrol study , 25 subject complete clinical phase study .</detailed_description>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>1 . All volunteer select study healthy men woman 18 year age old time dose 2 . The weight range exceed ± 20 % height body frame per Desirable Weights Adults 1983 Metropolitan Height Weight Table 3 . Each volunteer complete screening process within 28 day prior Period I dose . Consent document screen evaluation HIV antibody determination review , discuss , sign potential participant full implementation screen procedure 4 . If female : child bear potential , practice acceptable method birth control duration study judge investigator ( ) , condom , foam , jelly , diaphragm , intrauterine device ( IUD ) , abstinence ; postmenopausal least 1 year ; surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) 1 . Volunteers recent history drug alcohol addiction abuse 2 . Volunteers presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined clinical investigator ) 3 . Volunteers whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant 4 . Volunteers demonstrate positive hepatitis B surface antigen screen reactive HIV antibody screen 5 . Volunteers demonstrate positive drug abuse screen screen study 6 . Female volunteer demonstrate positive pregnancy screen 7 . Female volunteer currently breastfeed 8 . Volunteers history allergic response ( ) amoxicillin relate drug 9 . Volunteers history clinically significant allergy include drug allergy 10 . Volunteers clinically significant illness 4 week prior period I dose ( determined clinical investigator ) 11 . Volunteers currently use tobacco product 12 . Volunteers take drug know induce inhibit hepatic drug metabolism 30 day prior period I dose 13 . Volunteers report donate great 150 mL blood within 30 day prior period I dose . All subject advise donate blood four week complete study 14 . Volunteers donate plasma ( e.g . plasmapheresis ) within 14 day prior period I dose . All subject advise donate plasma four week complete study 15 . Volunteers report receive investigational drug within 30 day prior period I dose 16 . Volunteers report take systemic prescription medication 14 day prior period I dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Bioequivalence , amoxicillin 600mg fasting condition</keyword>
</DOC>